Lung cancer is the single largest cause of cancer deaths, with less than 15% of newly diagnosed patients surviving beyond 5 years. More than 80% of lung cancers do not respond favorably to chemotherapy. One of the primary clinical challenges is to overcome the tumor resistance to chemotherapeutic drugs. P53 tumor suppressor gene mutations are reported in a majority of lung cancers and loss of p53 function results in increased drug resistance and tumor relapse.
Lung cancer is the single largest cause of cancer deaths, with less than 15% of newly diagnosed patients surviving beyond 5 years. More than 80% of lung cancers do not respond favorably to chemotherapy. One of the primary clinical challenges is to overcome the tumor resistance to chemotherapeutic drugs. P53 tumor suppressor gene mutations are reported in a majority of lung cancers and loss of p53 function results in increased drug resistance and tumor relapse. 1 An approach postulated in recent years is p53 gene replacement into the tumor cells, which can then lead the cell into apoptosis as well as increase the sensitivity of the cells to chemotherapeutic drugs. 2, 3 Most anti-cancer drugs have been conventionally delivered via oral or intravenous routes. Biodistribution of the drugs through these delivery strategies is widespread, with the ratio of the drug deposited in the lungs being low. 4 A similar distribution of transgene expression in various tissues is observed after intravenous or intraperi- toneal delivery of vector-DNA complexes for gene therapy. 5 Another concern is the systemic toxicity observed after oral or intravenous routes of delivery. Aerosol delivery of genes and chemotherapeutic drugs represents a very promising technology to target the lungs specifically, increasing the pulmonary deposition and pharmacokinetic profile of the drugs and genes. 4, 6 We have previously demonstrated that polyethylenimine (PEI) can achieve high levels of transgene expression in the lungs after aerosol delivery, 6 with minimal toxicity or cytokine responses, 6, 7 and the dose delivered by aerosol has been shown to result in an anti-tumor effect in two different lung cancer models, using the p53 tumor suppressor gene. 8, 9 Also, we previously reported that aerosol delivery of a liposomal formulation of 9NC, a topoisomerase I inhibitor, can inhibit the growth of subcutaneous tumors as well as lung metastases. 10, 11 In this report, we demonstrate that sequential delivery of p53 and 9NC by aerosol can arrest the growth of established B16-F10 melanoma pulmonary metastases in experimental mice.
In order to study the combined effect of 9NC and p53 in vitro, B16-F10 cells grown in tissue culture plates were transfected with PEI-p53 or PEI-Neobam complexes (1 g/ml DNA concentration; complexes prepared at a N:P ratio of 5:1, the PEI nitrogen:DNA phosphate ratio can be calculated by taking into account that 1 g of DNA has 3 nmol of phosphate and 1 l of 0.1 M PEI solution has 100 nmol of amine nitrogen, and 10:1 N:P ratio corresponds to 1.29:1 PEI:DNA weight ratio. PEI-DNA complexes were prepared as described in Ref. We have previously demonstrated the efficacy of p53 gene and 9NC drug therapy as single agents for inhibition of B16-F10 lung metastases. 8, 10 Treatment of established lung metastases is a difficult challenge in clinical settings, and often requires multi-modality approaches. In this study, we evaluated the therapeutic effect of sequential delivery of PEI-p53 and 9NC-DLPC aerosol complexes on established B16-F10 melanoma lung metastases. C57BL/6 mice (7-8 weeks old, Harlan SpragueDawley, Houston, TX, USA) were injected via the tail vein with 25 000 B16-F10 cells on day 0. Starting on day 11 after tumor cell injection, when the tumor foci are well established in the lungs (not shown), the mice were treated twice a week with 9NC-DLPC and once a week with PEI-p53 aerosol complexes. Similar to in vitro studies, the p53 gene was delivered before the drug therapy (for combination therapy each week, the p53 was administered on Monday and 9NC was aerosolized on Tuesday and Friday). Animals in the single agent therapy group were administered p53 or 9NC twice a week. The dosage of treatment was 2 mg plasmid/10 ml of aerosolized solution at a PEI:DNA (N:P) ratio of 10:1 for DNA, and 5 mg 9NC at a concentration of 0.5 mg/ml at a 9NC:DLPC weight ratio of 1:50. Aerosol delivery of drugs and genes was performed using 5% CO 2 in air for increased pulmonary deposition as previously reported, 6, 12 and the DNA and 9NC deposited doses in the lungs of mice after aerosol delivery was also reported. 6, 12 Furthermore, immunohistochemistry for transgene expression shows that PEI-DNA complexes transfect the B16-F10 tumor foci in the lungs. 13 On day 25 after tumor inoculation, the mice were killed, lungs were fixed and the tumor index was calculated on the basis of a grading system described in the figure legend. The mice treated with the combination of p53 and 9NC had significantly lower tumor index (P Ͻ 0.001) compared with all other groups, whereas animals in all the other groups had large number of tumor nodules (Figure 2a ). All animals in the p53 and 9NC combination group had very small and distinct tumor foci (Figure 2b,c) . There was no effect of 5% CO 2 alone on the growth of tumors as compared with untreated mice (data not shown). The lung weights also revealed a significant difference (P Ͻ 0.01) between the combination group and all the other groups ( Figure 2d ).
Next we investigated if the therapy would prolong the mean survival time of mice challenged with B16-F10 cells. C57BL/6 mice were injected via the tail vein with 25 000 B16-F10 cells on day 0. The mice were treated with 9NC-DLPC and PEI-p53 complexes or their combination, starting day 11 after tumor cell injection as described above. The dosage was twice a week for drug or gene alone; and in combination once a week gene and twice a week drug therapy. The mice were treated for 2 weeks, and then monitored for their survival. As shown in Figure 3 , the mean survival time of the mice treated with both p53 and 9NC was increased by 30-40%, as compared with animals in other groups (37 + 6 days for 9NC + p53 as compared with 29 + 3 days for 9NC alone and 25 + 4 days for other groups). Furthermore, about 20% of mice in the p53 and 9NC combination group survived till day 50 after tumor inoculation and were tumor-free (no visible tumors in the lungs) when autopsied on day 52.
The data presented here demonstrate that aerosol delivery of PEI-p53 DNA and 9NC-DLPC complexes, in sequence, can achieve an enhanced therapeutic response in mice challenged with B16-F10 melanoma cells, as compared with single agent alone. The lung weights and tumor burden were significantly reduced in the mice treated with both p53 and 9NC, as compared with the other groups. Both the p53 gene and the camptothecins have been reported to inhibit subcutaneous tumor growth, as well as lung metastases, alone and in combi- nation with other agents. 8, 10, 11, 14, 15 Our data demonstrate for the first time that sequential aerosol delivery of p53 and 9NC can inhibit the growth of established B16-F10 lung metastases.
Figure 2 Effect of p53 and 9NC combination on growth of established B16-F10 lung metastases. (a) Tumor index was calculated by the formula: tumor index = lung weights × average grade for the group. Since most of the lungs in the control groups had numerous uncountable foci, the lungs were graded based on a scale of 1-5 as previously described; 8 1 if there are less than 10 tumor foci, 2 if there are 10-100 tumor foci, 3 if one lobe of the lung is full of tumor, 4 if both lobes are full of tumor, and 5 if the lungs are full of tumor and the tumor was growing out of the lungs and into the chest wall. The growth of tumor contiguous to the lung was considered as a part of the lung for weighing the lungs. Values are mean + s.d. (n = 10 mice per group). (b) Representative lungs from untreated (top row), p53 (middle row), and 9NC and p53 combination (bottom row) treated mice are presented (n = 10 mice per group). (c) Representative lungs from untreated (top), 9NC and
The combination effect of the 9NC and p53 could be attributed to various mechanisms. One possibility is that the p53 sensitizes the B16-F10 cells to 9NC-mediated apoptosis. Camptothecins are topoisomerase inhibitors, which induce apoptosis in tumor cells by inducing single strand breaks in the DNA. 16 P53 has been shown to sensitize various tumor cell lines to camptothecins, although CPT and analogs induce apoptosis in some cells lines via a p53 independent pathway. 17, 18 Additionally, Kalechman et al 19 have previously shown that AS101 (ammonium trichloror(dioxoethylene-0,0Ј)tellurate), can increase apoptosis in B16-F10 cells via up regulation of p53. A similar mechanism might be involved in our study where the transfection by PEI-p53 increases the level of p53 expression in B16-F10 cells, leading to increased sensitivity and additive anti-tumor effect with 9NC. We have previously demonstrated that aerosol delivery of PEI-p53 complexes leads to some evidence of apoptosis in the B16-F10 tumor foci in the lungs. 13 The possible apoptotic mechanism in B16-F10 tumor cells after 9NC and p53 treatment is currently under investigation.
Gene Therapy
The additive effect of 9NC and p53 could also be due to their anti-angiogenic mechanisms. Angiogenesis is required for a tumor to grow beyond 1-2 mm in diameter, 20 and suppression of angiogenesis is a novel way to potentially shrink or eliminate established and metastatic tumors. Camptothecins have been shown to inhibit tumor growth through modulation of angiogenesis by damaging the actively growing new blood vessels in the tumors. 21, 22 P53 has been shown to be a key regulator of angiogenesis by transcriptional control of various angiogenic factors, such as vascular endothelial growth factor (VEGF) and anti-angiogenic factors such as thrombospondin-1 (TSP-1). 23, 24 Studies from our laboratory reveal that B16-F10 cell line is highly angiogenic in vivo, and p53 transfection of B16-F10 cells can reverse this angiogenic phenotype and inhibit tumor growth through downregulation of VEGF and up-regulation of TSP-1. 13 It is possible that the increased anti-angiogenesis due to the combined effect of p53 and 9NC results in growth inhibition of tumor metastases. Further studies are underway in our laboratory to delineate the 9NC and p53 interaction that leads to this combined anti-tumor effect.
We have previously demonstrated that aerosol delivery of 9NC-DLPC results in inhibition of B16-F10 lung metastases. 10 The dose delivered in that study was much higher (5 days a week, twice daily with the same dose as reported here), and the treatment was started on day 1 after tumor inoculation. Similarly, aerosol delivery of PEI-p53 DNA complexes lead to a significant inhibition of B16-F10 pulmonary metastases when the treatment was started on day 1 after tumor inoculation with a twice a week regimen. 8 In contrast, we demonstrate in this study that a much lower dose of p53 and 9NC is required to inhibit the growth of established B16-F10 lung metastases when delivered in sequence, although the single agent alone was not potent enough to suppress metastatic growth or increase the survival of tumor-bearing mice. One modification we did over the previous study with 9NC therapy was the aerosol delivery of the drug with 5% CO 2 leading to increased pulmonary deposition and pharmacokinetics of 9NC. 12 Furthermore, this experimental model closely replicates a clinical situation where patients present with established pulmonary tumors, and treatment of such a disease often requires a multimodality intervention. Additionally, the dosage regimen that was found to be effective encompassed delivery of PEI-p53 before treatment with 9NC-DLPC, rather than drug before gene, possibly due to the observation that delivery of liposomal drug formulations results in decreased transgene expression levels and a refractory period for PEI-DNA aerosol delivery (Densmore, unpublished data) .
Studies by other groups have demonstrated that p53 can sensitize the tumors to anti-cancer agents in animal models, 25 and some of these combination studies are also being incorporated into initial phases of clinical trials. 26 Fujiwara et al 25 have demonstrated that p53 can sensitize tumor cells to the DNA-damaging drug, cisplatinum, both in vitro and in vivo. A modest clinical benefit was also demonstrated using this approach in clinical trials. 26 The p53 gene in these studies was delivered using cationic liposomes or adenoviruses. Moreover, the technique used for administering gene delivery vectors to lung cancer patients is mainly through intratumoral injections by use of computed tomography-guided percutaneous fineneedle injections or bronchoscopy. 26, 27 Although most of these studies show some therapeutic response, they are rather invasive techniques. The study presented here is the first one to demonstrate the additive effect of p53 and 9NC delivered by aerosol in arresting established lung metastases. Since most of the gene transfection is localized in the bronchial epithelium, 13 a direct effect of p53 expression is highly likely for the tumors of bronchial and alveolar epithelium. However, as we have reported in our recent study, 13 the role of anti-angiogenic factors regulated by p53 in tumor suppression is also important, and would be an indirect effect on tumor growth in any of the pulmonary sites, even possibly for p53-positive tumors such as small cell lung carcinoma (SCLC). The 9NC delivery would further have an added inhibitory effect on tumor growth. Preliminary studies from our laboratory demonstrate that p53 might sensitize tumor cells to other anti-cancer drugs such as paclitaxel, as well as to irradiation therapy (Koshkina, unpublished data) . Based on the data presented here, we propose that aerosol delivery of PEI-p53 DNA complexes in sequence with anti-cancer drugs is an attractive alternative to conventional therapies for lung cancer.
